Dec 09, 2017 17:30 pm UTC| Business
One-time Engineering Event Using iPSCs and CRISPR/Cas9 Yields Genetically Modified, Self-Renewing Clonal Master Pluripotent Cell Line Master Pluripotent Cell Line Engineered with Complete Elimination of TCR Expression...
Dec 09, 2017 17:15 pm UTC| Business
CAMBRIDGE, Mass. and BEIJING, China, Dec. 09, 2017 -- BeiGene, Ltd. (NASDAQ:BGNE), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly targeted and...
GBT Announces New Phase 2a Data at ASH for Voxelotor in Adolescents with Sickle Cell Disease (SCD)
Dec 09, 2017 15:00 pm UTC| Business
SOUTH SAN FRANCISCO, Calif., Dec. 09, 2017 -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced new results from its ongoing Phase 2a HOPE-KIDS 1 Study of once-daily oral therapy, voxelotor...
Dec 09, 2017 14:30 pm UTC| Business
Subcutaneous (SQ) delivery significantly increases half-life of CB 2679d to 98.7 hours Data supports potential normalization of FIX activity with daily or less-frequent SQ dosing SOUTH SAN FRANCISCO, Calif., Dec. 09,...
Dec 09, 2017 14:00 pm UTC| Business
Non-human primate study of AMT-061 utilizing FIX-Padua shows 6.5-fold increase in FIX clotting activitycompared to AMT-060 Data supports nonclinical comparability plan agreed upon with FDA LEXINGTON, Mass. and...
Dec 09, 2017 14:00 pm UTC| Business
CAMBRIDGE, Mass. and BEIJING, China, Dec. 09, 2017 -- BeiGene, Ltd. (NASDAQ:BGNE), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly targeted and...
Dec 09, 2017 13:30 pm UTC| Business
NEW YORK, Dec. 09, 2017 -- Pomerantz LLP announces that a class action lawsuit has been filed against Alkermes plc (“Alkermes” or the “Company”) (NASDAQ:ALKS) and certain of its officers. The class action, filed in...